Novartis received approval from the FDA for Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people 11 to 55 years of age. “The FDA approval of Menveo is an important milestone for adolescent immunization in the U.S. According to CDC estimates, approximately 16 million adolescents b...